MiR-148a在国人血浆中的分布及与高脂血症的关联性探讨

中国临床药理学与治疗学 ›› 2017, Vol. 22 ›› Issue (6): 659-663.

MiR-148a在国人血浆中的分布及与高脂血症的关联性探讨

李西^1,2，靳高凤^1,2，刘志军^1,2，李新华³，刘名义^1,2，张红^1,2，熊玉卿^1,2

¹南昌大学临床药理研究所，²江西省临床药物代谢动力学重点实验室，³南昌大学医院，南昌 330006，江西

收稿日期:2016-07-13 修回日期:2016-10-26 出版日期:2017-06-26 发布日期:2017-06-26
通讯作者: 熊玉卿，女，教授，博士生导师，研究方向:临床药理学与药物代谢动力学。 Tel: 0791-86361081 E-mail:xyqh2629@163.com
作者简介:李西，女，硕士研究生，研究方向:临床药理学研究。 E-mail：410748005@qq.com
基金资助:
国家自然科学基金项目（81260508）；江西省“赣鄱英才555工程”人才资助计划（18000046）

Relevance of plasma distribution of microRNA-148a in Chinese population and hyperlipidemia

LI Xi ^1,2, JIN Gaofeng ^1,2, LIU Zhijun ^1,2, LI Xinhua ³, LIU Mingyi ^1,2, ZHANG Hong ^1,2, XIONG Yuqing ^1,2

¹Clinical Pharmacology Institute of Nanchang University，²Clinical Pharmacokinetics Key Laboratory of Jiangxi Province, ³ the Hospital of Nanchang University, Nanchang 330006, Jiangxi, China

Received:2016-07-13 Revised:2016-10-26 Online:2017-06-26 Published:2017-06-26

摘要/Abstract

摘要：

目的: 探讨国人血浆中microRNA-148a的分布情况，研究健康受试者与高脂血症患者血浆中miR-148a的表达水平的差异性。方法: 按临床试验方案收集高脂血症患者血浆样本52例及招募的健康受试者血浆样本77例，采用RT-qPCR测定miR-148a表达水平；以Shapiro-Wilk test对所得实验数据进行正态性检验，两组间采用两独立样本t检验，多组间数据利用one-way ANOVA进行分析。结果:129例受试者血浆中miR-148a表达水平按四分位数分组后，各组的表达水平△Ct分别为1.65±0.80、3.91±0.64、5.68±0.61和8.21±1.16，各组间的差异具有统计学意义（P<0.05）；而健康受试者组和高脂血症患者组血浆中miR-148a的表达水平△Ct分别为4.81±2.75和4.84±2.26，两组间差异无统计学意义（P>0.05）。结论: 国人血浆中miR-148a的表达水平呈正态分布且各组间的差异具有统计学意义；但健康组与高脂血症患者组血浆中miR-148a的表达差异无统计学意义，提示人体血浆中miR-148a的表达与高脂血症可能无关。

关键词: miR-148a, 表达水平, 分布, RT-qPCR, 高脂血症

Abstract:

AIM:To detect the distribution of miR-148a level in Chinese people's plasma, and to explore the different expression level of miR-148a in plasma between healthy subjects and hyperlipidemia patients. METHODS: According to the clinical trial scheme, plasma samples of 52 patients with hyperlipidemia and 77 cases of healthy subjects were collected. RT-qPCR was used to determine the expression of miR-148a level. Shapiro-Wilk test as a way of normality test to the experimental data. Two independent sample t-test or one-way ANOVA was used to analyze the difference between groups. RESULTS:129 cases of subjects were quartile grouped by miR-148a level, and the △Ct of miR-148a were 1.65±0.80，3.91±0.64，5.68±0.61 and 8.21±1.16, respectively. The difference between groups was statistically significant (P<0.05). Whereas, the △Ct of miR-148a of the healthy subjects group and patients with hyperlipidemia group were 4.81±2.75 and 4.84±2.26, respectively. There was no statistically significant difference between the two groups (P>0.05).CONCLUSION: The expression of miR-148a in Chinese people's plasma is normally distributed, and the difference between four groups is statistically significant. There is no difference between healthy subjects group and patients with hyperlipidemia group, suggesting that miR-148a may not relate to hyperlipidemia.

Key words: miR-148a, expression level, distribution, Real-time quantitative polymerase chain reaction, hyperlipidemia

中图分类号:

R968

李西，靳高凤，刘志军，李新华，刘名义，张红，熊玉卿. MiR-148a在国人血浆中的分布及与高脂血症的关联性探讨[J]. 中国临床药理学与治疗学, 2017, 22(6): 659-663.

LI Xi, JIN Gaofeng, LIU Zhijun, LI Xinhua, LIU Mingyi, ZHANG Hong, XIONG Yuqing. Relevance of plasma distribution of microRNA-148a in Chinese population and hyperlipidemia[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2017, 22(6): 659-663.

参考文献

［1］Lawrie CH, Gal S, Dunlop HM, et al. Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma［J］.Br J Haematol，2008, 141(5): 672-675.
［2］Kloosterman WP, Plasterk RH.The diverse functions of micrornas in animal development and disease［J］. Dev Cell, 2006, 11(4):441-450.
［3］Stefani G, Slack FJ. Small non-coding RNAs in animal development［J］. Nat Rev Mol Cell Biol, 2008, 9(3):219-230.
［4］Wagschal A, Najafi-Shoushtari SH, Wang L, et al.Genome-wide identification of microRNAs regulating cholesterol and triglyceride homeostasis［J］. Nat Med, 2015, 21(11)：1290-1297.
［5］高军平, 向邦德, 倪航航, 等. microRNA-224在肝细胞癌组织和血浆中表达的相关性［J］.中国现代医学杂志, 2011, 21(32): 4012-4016.
［6］Ruoquan Y, Wanpin N, Qiangsheng X, et al.Correlation between plasma miR-122 expression and liver injury induced by hepatectomy［J］.J Int Med Res，2014,42(1):77-84.
［7］Takeuchi-Yorimoto A, Yamaura Y, Kanki M, et al. MicroRNA-21 is associated with fibrosis in a rat model of nonalcoholic steatohepatitis and serves as a plasma biomarker for fibrotic liver disease［J］. Toxicol Lett,2016, 258: 159-167.
［8］Chen Y, Song YX, Wang ZN. The microRNA-148/152 family: multi-faceted players［J］. Mol Cancer, 2013, 12(1): 43.
［9］Goedeke L, Rotllan N, Canfrán-Duque A, et al. MicroRNA-148a regulates LDL receptor and ABCA1 expression to control circulating lipoprotein levels［J］. Nat Med,2015, 21(11):1280-1289.
［10］Rotllan N, Price N, Pati P, et al.MicroRNAs in lipoprotein metabolism and cardiometabolic disorders［J］. Atherosclerosis, 2016, 246(10): 352-360.
［11］Mitchell PS, Parkin RK, Kroh EM, et al.Circulating microRNAs as stable blood-based markers for cancer detection［J］. Proc Natl Acad Sci USA,2008, 105(30):10513-10518.
［12］Resnick KE, Alder H, Hagan JP, et al. The detection of differentially expressed microRNAs from the serum of ovarian cancer patients using a novel real-time PCR platform［J］.Gynecol Oncol, 2009, 112(1):55-59.
［13］吴瑞珊, 温旺荣.外周血miRNA的诊断意义［J］.分子诊断与治疗杂志, 2012, 4(2): 131-136.
［14］Kroh EM, Parkin RK, Mitchell PS, et al.Analysis of circulating microRNAbiomarkers in plasma and serum using quantitative reverse transcription-PCR (qRT-PCR)［J］.Methods, 2010, 50(4):298-301.

[1]	赵璐, 李付勇, 温滨红, 李道伟. 他汀类药物治疗伴高脂血症偏头痛患者的临床疗效分析[J]. 中国临床药理学与治疗学, 2023, 28(6): 671-675.
[2]	吴志勇, 刘兵荣, 李彬, 汤睿. 红细胞分布宽度对急性缺血性卒中静脉溶栓早期神经功能改善不良的预测作用[J]. 中国临床药理学与治疗学, 2023, 28(3): 307-314.
[3]	郭璐, 钟振东, 韩奕岑, 石毅, 杨勇, 边原, 刘晓姝, 张静, 郎琴, 钟甜. 不同给药方式在大鼠内对利巴韦林的药代动力学和组织分布的影响[J]. 中国临床药理学与治疗学, 2022, 27(1): 25-32.
[4]	许可, 高骏伟, 刘鹏, 申正日, 贾慧, 吴宸广, 田锋, 王立范, 李平. 糖肾方激活PGC-1α/LXR/ABCA1信号通路改善高脂诱导的巨噬细胞胆固醇摄取及流出[J]. 中国临床药理学与治疗学, 2021, 26(9): 978-985.
[5]	王香溢, 盛洁, 王秀, 郭岩, 陈志武. UPLC-MS/MS法测定氘代氯化琥珀胆碱在大鼠体内分布[J]. 中国临床药理学与治疗学, 2021, 26(3): 271-277.
[6]	陈爱瑛, 程敏, 繆云萍, 叶小弟, 田雪君, 郑高利. 舒尼替尼药代动力学和脑肾组织分布特征[J]. 中国临床药理学与治疗学, 2020, 25(10): 1105-1110.
[7]	邢晗，宁晨，孔德璇，蔡卉，周时雨，任畅，孔颖，程钰洁，陈西敬. 高抗肿瘤活性汉黄芩素衍生物GL-V9在大鼠体内的组织分布和排泄研究[J]. 中国临床药理学与治疗学, 2019, 24(8): 889-895.
[8]	袁雅文，李岩，杨劲. LC-MS/MS法测定对氨基水杨酸浓度及在大鼠组织分布研究中的应用[J]. 中国临床药理学与治疗学, 2017, 22(3): 272-280.
[9]	姚天怡, 尹少平, 刘雯, 赵炎磊, 王广基, 李娟. 紫杉醇聚合物胶束的组织分布和生物学评价[J]. 中国临床药理学与治疗学, 2017, 22(11): 1207-1214.
[10]	杨毅，官俏兵，郭丽，李文燕，张慧，韩晨阳. 依折麦布与考来替泊交替给药对于高脂血症大鼠脂代谢的调节作用[J]. 中国临床药理学与治疗学, 2017, 22(10): 1112-1116.
[11]	姜海，姜国志，陈钟，李振江. 姜黄提取物联合阿托伐他汀钙对高脂血症小鼠降血脂作用的研究[J]. 中国临床药理学与治疗学, 2017, 22(1): 48-51.
[12]	高家林，张魏，刘春生，朱玉，张斌华，夏礼斌，陈月平，邢春燕，王勇. 皖南地区1831例中老年糖尿病合并尿路感染病原菌分布、耐药情况及治疗对策[J]. 中国临床药理学与治疗学, 2016, 21(6): 678-683.
[13]	云彪，牛慧云，杜志强，任志生，杨玉梅，田彩云. 纯康血脂胶囊对高脂血症大鼠肝损伤的保护作用[J]. 中国临床药理学与治疗学, 2016, 21(10): 1114-1117.
[14]	刘敏, 肖飞燕, 王晓飞, 张伟, 周淦. 基因多态性、药物联用和临床因素对氯吡格雷疗效的影响及相关的基因型分布[J]. 中国临床药理学与治疗学, 2015, 20(8): 915-922.
[15]	唐志华, 王玮, 丁洁卫. 雾化吸入氨茶碱在犬体内的组织分布[J]. 中国临床药理学与治疗学, 2014, 19(2): 150-155.